Add-on astragalus in type 2 diabetes and chronic kidney disease: A multi-center, assessor-blind, randomized controlled trial

• Published in: Phytomedicine (Stuttgart) 2024-07, Vol.130, p.155457, Article 155457
• Main Authors: Chan, Kam Wa, Kwong, Alfred Siu Kei, Tsui, Pun Nang, Chan, Gary Chi Wang, Choi, Wing Fai, Yiu, Wai Han, Cheung, Simon Chi Yuen, Wong, Michelle Man Ying, Zhang, Zhang-Jin, Tan, Kathryn Choon Beng, Lao, Lixing, Lai, Kar Neng, Tang, Sydney Chi Wai
• Format: Article
• Language: English
• Subjects: Aged; Albuminuria - drug therapy; Astragalus; Astragalus Plant - chemistry; biomarkers; blood; China; Chinese medicine; Chronic kidney disease; Clinical trial; clinical trials; Creatinine - blood; Creatinine - urine; Diabetes; Diabetes Mellitus, Type 2 - drug therapy; Diabetic Nephropathies - drug therapy; dialysis; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Female; food composition; glomerular filtration rate; Glomerular Filtration Rate - drug effects; herbal medicines; Hong Kong; Humans; Integrative medicine; kidneys; Male; Middle Aged; noninsulin-dependent diabetes mellitus; Phytotherapy; Pragmatic; renal failure; Renal Insufficiency, Chronic - drug therapy; sample size; systolic blood pressure
• ISSN: 0944-7113; 1618-095X; 1618-095X
• DOI: 10.1016/j.phymed.2024.155457

Diabetes leads to chronic kidney disease (CKD) and kidney failure, requiring dialysis or transplantation. Astragalus, a common herbal medicine and US pharmacopeia-registered food ingredient, is shown kidney protective by retrospective and preclinical data but with limited long-term prospective clinical evidence. This trial aimed to assess the effectiveness of astragalus on kidney function decline in macroalbuminuric diabetic CKD patients. This randomized, assessor-blind, standard care-controlled, multi-center clinical trial randomly assigned 118 patients with estimated glomerular filtration rate (eGFR) of 30–90 ml/min/1.73m2 and urinary albumin-to-creatinine ratio (UACR) of 300–5000 mg/g from 7 public outpatient clinics and the community in Hong Kong between July 2018 and April 2022 to add-on oral astragalus granules (15 gs of raw herbs daily equivalent) or to continue standard care alone as control for 48 weeks. Primary outcomes were the slope of change of eGFR (used for sample size calculation) and UACR of the intention-to-treat population. Secondary outcomes included endpoint blood pressures, biochemistry, biomarkers, concomitant drug change and adverse events. (ClinicalTrials.gov: NCT03535935) During the 48-week period, the estimated difference in the slope of eGFR decline was 4.6 ml/min/1.73m2 per year (95 %CI: 1.5 to 7.6, p = 0.003) slower with astragalus. For UACR, the estimated inter-group proportional difference in the slope of change was insignificant (1.14, 95 %CI: 0.85 to 1.52, p = 0.392). 117 adverse events from 31 astragalus-treated patients and 41 standard care-controlled patients were documented. The 48-week endpoint systolic blood pressure was 7.9 mmHg lower (95 %CI: -12.9 to -2.8, p = 0.003) in the astragalus-treated patients. 113 (96 %) and 107 (91 %) patients had post-randomization and endpoint primary outcome measures, respectively. In patients with type 2 diabetes, stage 2 to 3 CKD and macroalbuminuria, add-on astragalus for 48 weeks further stabilized kidney function on top of standard care.